Quantification of the endogenous growth hormone and prolactin lowering effects of a somatostatin-dopamine chimera using population PK/PD modeling
Open Access
- 4 April 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 47 (3), 229-239
- https://doi.org/10.1007/s10928-020-09683-3
Abstract
A phase 1 clinical trial in healthy male volunteers was conducted with a somatostatin-dopamine chimera (BIM23B065), from which information could be obtained on the concentration-effect relationship of the inhibition of pulsatile endogenous growth hormone and prolactin secretion. Endogenous growth hormone profiles were analyzed using a two-step deconvolution-analysis-informed population pharmacodynamic modeling approach, which was developed for the analyses of pulsatile profiles. Prolactin concentrations were modelled using a population pool model with a circadian component on the prolactin release. During treatment with BIM23B065, growth hormone secretion was significantly reduced (maximal effect [EMAX] = − 64.8%) with significant reductions in the pulse frequency in two out of three multiple ascending dose cohorts. A circadian component in prolactin secretion was identified, modelled using a combination of two cosine functions with 24 h and 12 h periods. Dosing of BIM23B065 strongly inhibited (EMAX = − 91%) the prolactin release and demonstrated further reduction of prolactin secretion after multiple days of dosing. This study quantified the concentration-effect relationship of BIM23B065 on the release of two pituitary hormones, providing proof of pharmacology of the chimeric actions of BIM23B065.Keywords
Funding Information
- Ipsen Biopharmaceuticals
This publication has 20 references indexed in Scilit:
- Basic Concepts in Population Modeling, Simulation, and Model‐Based Drug Development: Part 3—Introduction to Pharmacodynamic Modeling MethodsCPT: Pharmacometrics & Systems Pharmacology, 2014
- A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteersDrug Design, Development and Therapy, 2012
- Pharmacodynamic Modeling of the Effects of Lanreotide Autogel on Growth Hormone and Insulin‐Like Growth Factor 1The Journal of Clinical Pharmacology, 2012
- Circadian system, sleep and endocrinologyMolecular and Cellular Endocrinology, 2012
- Somatostatin-Dopamine Chimeras: A Novel Approach to Treatment of Neuroendocrine TumorsHormone and Metabolic Research, 2011
- Comparison of the agonist-antagonist interaction model and the pool model for the effect of remoxipride on prolactinBritish Journal of Clinical Pharmacology, 2010
- Acromegaly pathogenesis and treatmentJCI Insight, 2009
- How genomics has informed our understanding of the pathogenesis of osteoporosisGenome Medicine, 2009
- AcromegalyEndocrinology and Metabolism Clinics of North America, 2008
- Perl-speaks-NONMEM (PsN)—a Perl module for NONMEM related programmingComputer Methods and Programs in Biomedicine, 2004